From a therapeutic standpoint, this opens new opportunities: targeting Ap4A metabolism—either by inhibiting NUDT2 or administering stable Ap4A analogs—could modulate gene expression in a way that suppresses tumorigenesis or sensitizes cancer cells to treatment. Here, NUDT2 is linked to cancer.